Ensysce Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENSC Nasdaq 2836 www.ensysce.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ensysce Biosciences, Inc.

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Jan 8th, 2026 6:00 am
Ensysce Biosciences Issues Annual Shareholder Letter - Jan 5th, 2026 6:00 am
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - Dec 12th, 2025 6:00 am
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Dec 9th, 2025 6:00 am
ENSC Enrolls First Patient in Critical Phase 3 Trial - Dec 9th, 2025 4:24 am
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Dec 2nd, 2025 6:00 am
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach - Nov 20th, 2025 6:00 am
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs - Nov 17th, 2025 6:05 am
ENSC Bolsters Balance Sheet for Commercialization Push - Nov 17th, 2025 4:06 am
Ensysce Biosciences Reports Third Quarter 2025 Financial Results - Nov 14th, 2025 2:15 pm
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025 - Oct 10th, 2025 6:00 am
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium - Sep 4th, 2025 6:00 am
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025 - Aug 19th, 2025 6:00 am
Ensysce Biosciences Second Quarter 2025 Earnings: Beats Expectations - Aug 15th, 2025 5:53 am
ENSC Focused on Bringing Change to Pain Relief Market - Aug 14th, 2025 4:21 am
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates - Aug 13th, 2025 2:15 pm
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback - Jul 31st, 2025 6:00 am
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse - Jul 16th, 2025 6:00 am
ENSC Start Phase 3 Trial on Abuse-Resistant Pain Reliever - Jul 16th, 2025 5:07 am
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 - Jun 24th, 2025 6:00 am